Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment - PubMed (original) (raw)
Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment
M J Hurley et al. Brain Res. 1996.
Abstract
The distribution of the dopamine D3 receptor was studied by receptor autoradiography using [3H]7-OH-DPAT in striatal and extrastriatal brain regions of the common marmoset (Callithrix jacchus). Saturation studies demonstrated that [3H]7-OH-DPAT bound with similar affinity to different regions of marmoset brain. In normal marmosets, specific [3H]7-OH-DPAT binding was found in both striatal and extrastriatal regions. Very high levels of specific [3H]7-OH-DPAT binding were detected in the islands of Calleja and nucleus accumbens but in addition high levels of binding were detected in rostral caudate nucleus and putamen. In common marmosets treated with the selective nigral neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), the levels of specific [3H]7-OH-DPAT binding in striatal and extrastriatal regions were not different to those in normal animals. Chronic treatment of MPTP-treated marmosets with L-DOPA/ carbidopa did not alter the levels of specific [3H]7-OH-DPAT binding in any brain region. These results demonstrate that in common marmosets D3 receptors are located in both striatal and limbic regions. The receptor density is not altered by dopaminergic denervation or by chronic L-DOPA administration. The D3 receptor may, therefore, be important in both the therapeutic and adverse effects of drugs used to treat Parkinson's disease.
Similar articles
- Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Gnanalingham KK, Smith LA, Hunter AJ, Jenner P, Marsden CD. Gnanalingham KK, et al. Synapse. 1993 Jun;14(2):184-94. doi: 10.1002/syn.890140212. Synapse. 1993. PMID: 8332947 - Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets.
Lastres-Becker I, Cebeira M, de Ceballos ML, Zeng BY, Jenner P, Ramos JA, Fernández-Ruiz JJ. Lastres-Becker I, et al. Eur J Neurosci. 2001 Dec;14(11):1827-32. doi: 10.1046/j.0953-816x.2001.01812.x. Eur J Neurosci. 2001. PMID: 11860478 - Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Morin N, Jourdain VA, Morissette M, Grégoire L, Di Paolo T. Morin N, et al. Neuropharmacology. 2014 Apr;79:688-706. doi: 10.1016/j.neuropharm.2014.01.014. Epub 2014 Jan 20. Neuropharmacology. 2014. PMID: 24456747 - 5-HT2A blockade for dyskinesia and psychosis in Parkinson's disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review.
Kwan C, Frouni I, Bédard D, Nuara SG, Gourdon JC, Hamadjida A, Huot P. Kwan C, et al. Exp Brain Res. 2019 Feb;237(2):435-442. doi: 10.1007/s00221-018-5434-9. Epub 2018 Nov 15. Exp Brain Res. 2019. PMID: 30443669 Review. - [Application of the common marmoset to pharmacological studies].
Nomoto M. Nomoto M. Nihon Yakurigaku Zasshi. 1995 Jul;106(1):11-8. doi: 10.1254/fpj.106.11. Nihon Yakurigaku Zasshi. 1995. PMID: 7590519 Review. Japanese.
Cited by
- Striatal Signaling in L-DOPA-Induced Dyskinesia: Common Mechanisms with Drug Abuse and Long Term Memory Involving D1 Dopamine Receptor Stimulation.
Murer MG, Moratalla R. Murer MG, et al. Front Neuroanat. 2011 Aug 11;5:51. doi: 10.3389/fnana.2011.00051. eCollection 2011. Front Neuroanat. 2011. PMID: 21886608 Free PMC article. - Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain.
Sun J, Xu J, Cairns NJ, Perlmutter JS, Mach RH. Sun J, et al. PLoS One. 2012;7(11):e49483. doi: 10.1371/journal.pone.0049483. Epub 2012 Nov 21. PLoS One. 2012. PMID: 23185343 Free PMC article. - Regulation of dopamine D₃ receptor in the striatal regions and substantia nigra in diffuse Lewy body disease.
Sun J, Cairns NJ, Perlmutter JS, Mach RH, Xu J. Sun J, et al. Neuroscience. 2013 Sep 17;248:112-26. doi: 10.1016/j.neuroscience.2013.05.048. Epub 2013 Jun 1. Neuroscience. 2013. PMID: 23732230 Free PMC article. - Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.
Coldwell MC, Boyfield I, Brown T, Hagan JJ, Middlemiss DN. Coldwell MC, et al. Br J Pharmacol. 1999 Aug;127(7):1696-702. doi: 10.1038/sj.bjp.0702673. Br J Pharmacol. 1999. PMID: 10455328 Free PMC article. - Extrastriatal D2-like receptors modulate basal ganglia pathways in normal and Parkinsonian monkeys.
Hadipour-Niktarash A, Rommelfanger KS, Masilamoni GJ, Smith Y, Wichmann T. Hadipour-Niktarash A, et al. J Neurophysiol. 2012 Mar;107(5):1500-12. doi: 10.1152/jn.00348.2011. Epub 2011 Nov 30. J Neurophysiol. 2012. PMID: 22131382 Free PMC article.